Barclays analyst Gena Wang downgraded BioCryst Pharma (NASDAQ: BCRX) from Overweight to Equalweight with a price target of $13.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE